China’s First Long-Acting RSV Preventive Antibody Approved

This approval marks a meaningful step for China's biopharma sector, as it introduces a domestically developed alternative in the RSV prevention space, a category that has seen global demand. The strategic partnership behind the drug highlights how collaborative R&D models are becoming central to bringing complex biologics to market. For industry watchers, the focus now shifts to how this product is positioned commercially, including pricing and distribution, and whether it prompts faster regulatory timelines for similar preventive antibodies in the pipeline.